中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

47 records (took 0.024 seconds)

    METHOD OF USING POTASSIUM CHANNEL INHIBITING COMPOUNDS
    3.
    发明申请
    METHOD OF USING POTASSIUM CHANNEL INHIBITING COMPOUNDS 审中-公开
    使用钾通道抑制化合物的方法

    公开(公告)号：WO2007020286A3

    公开(公告)日：2007-05-10

    申请号：PCT/EP2006065418

    申请日：2006-08-17

    Applicant: SOLVAY PHARM GMBH ,  ANTEL JOCHEN ,  GREGORY PETER-COLIN ,  FIRNGES MICHAEL ,  REICHE DANIA

    Inventor： ANTEL JOCHEN ,  GREGORY PETER-COLIN ,  FIRNGES MICHAEL ,  REICHE DANIA

    IPC: A61K31/549 ,  A61K31/085 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/5383 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/06 ,  A61P13/10 ,  A61P17/14 ,  A61P25/00 ,  A61P25/08

    CPC classification number: A61K31/425 ,  A61K31/085 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/5383 ,  A61K31/549 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention relates to the use of an effective amount of at least one potassium KvI.3 channel inhibitor or of an effective amount of at least one compound having in addition to its potassium KvI.3 channel inhibiting properties also CBx modulating properties and/or potassium K(atp) channel opening properties for the manufacture of a medicament for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of various medical conditions in subjects in need thereof . The diseases are obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, glucose metabolism - in particular, insulin resistance, hyperglycaemea and/or glucose intolerance - neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence. The compounds are a.o. 4, 5-dihydropyrazole derivatives, imidazole derivatives, diazoxide, NN414, R(+) -WIN55212-2, HU-308, Rimonaband, SR-147778.

    Abstract translation: 本发明涉及使用有效量的至少一种KvI.3通道抑制剂或有效量的至少一种化合物，除了其KvI.3通道抑制性质之外，还具有CBx调节性质和/或 钾（atp）通道开放性质，用于制备用于在有需要的受试者中预防，治疗，延迟进展，延迟发作和/或抑制各种医学病症的药物。 疾病是肥胖症，糖尿病，代谢综合征，综合征X，胰岛素瘤，家族性高胰岛素血症，男性型秃发，逼尿肌反应性过高，哮喘，葡萄糖代谢 - 特别是胰岛素抵抗，高血糖和/或葡萄糖不耐受 - 神经保护，癫痫，止痛 心脏保护，心绞痛，心脏停搏，心律失常，冠状动脉痉挛，外周血管疾病，脑血管痉挛，食欲调节，神经变性，疼痛 - 包括神经性疼痛和慢性疼痛 - 阳。。 化合物是a.o. 4,5-二氢吡唑衍生物，咪唑衍生物，二氮嗪，NN414，R（+）-WIN55212-2，HU-308，Rimonaband，SR-147778。

    COMPUESTOS FARMACEUTICOS QUE COMPRENDEN MODULADORES DE RECEPTORES DE CANABINOIDE CBX Y MODULADORES DE CANAL DE POTASIO.
    4.
    发明专利
    COMPUESTOS FARMACEUTICOS QUE COMPRENDEN MODULADORES DE RECEPTORES DE CANABINOIDE CBX Y MODULADORES DE CANAL DE POTASIO. 未知

    公开(公告)号：MX2008013678A

    公开(公告)日：2008-11-04

    申请号：MX2008013678

    申请日：2007-04-20

    Applicant: SOLVAY PHARM GMBH

    Inventor： ANTEL JOCHEN ,  LANGE JOSEPHUS HUBERTUS MARIA ,  GREGORY PETER-COLLIN ,  FIRNGES MICHAEL ,  REICHE DANIA

    IPC: A61K31/415 ,  A61K31/045 ,  A61K31/426 ,  A61P3/00 ,  A61P9/00

    Abstract: La invención se refiere a composiciones farmacéuticas que comprenden cantidades farmacológicamente eficaces de cada uno de a) al menos un modulador de canal de KATP como un primera sustancia activa y b) al menos un modulador de CBx como segunda sustancia activa. La invención también se refiere al uso de dichas composiciones y al método de tratar, prevenir, retardar el progreso o retardar la iniciación y/o inhibir una variedad de condiciones patológicas que incluyen obesidad, diabetes mellitus, síndrome metabólico, síndrome X, insulinoma, hipoglicemia hipennsulémica familiar, modelo de calvicie masculina, hiperreactividad de detrusor, asma, neuroprotecdón, epilepsia, analgesia, cardioprotección, angina, cardioplegia, arritmia, espasmo coronario, hipertensión, enfermedad vascular periférica, vasoespasmo cerebral, regulación del apetito, neurodegeneración, dolor - incluyendo dolor neuropático y dolor crónico- e impotencia en mamíferos y seres humanos por administración de dichas composiciones a sujetos que lo necesitan . La invención también se refiere a un procedimiento de manufactura de dichas composiciones.

    7.
    发明专利
    未知

    公开(公告)号：NO20072659L

    公开(公告)日：2007-05-24

    申请号：NO20072659

    申请日：2007-05-24

    Applicant: SOLVAY PHARM GMBH

    Inventor： GREGORY PETER-COLIN ,  WALDECK HARALD ,  ANTEL JOCHEN ,  FIRNGES MICHAEL ,  LANGE JOSEPHUS HUBERTUS MARIA

    IPC: A61K31/40 ,  A61K31/415 ,  A61K31/427 ,  A61K31/44 ,  A61K31/54 ,  A61P3/04 ,  A61P3/10

    Abstract: Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one KATP channel opener as a first active agent and at least one CB1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATP channel opening and CB1 antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising KATP channel openers and CB1 antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type I, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhibition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined KATP channel opening and CB1 antagonistic properties.

    8.
    发明专利
    未知

    公开(公告)号：BRPI0711064A2

    公开(公告)日：2011-08-23

    申请号：BRPI0711064

    申请日：2007-04-20

    Applicant: SOLVAY PHARM GMBH

    Inventor： GREGORY PETER-COLIN ,  LANGE JOSEPHUS HUBERTUS MARIA ,  FIRNGES MICHAEL ,  REICHE DANIA ,  ANTEL JOCHEN

    IPC: A61K31/145 ,  A61K31/045 ,  A61K31/426 ,  A61P3/00 ,  A61P9/00

    Abstract: The invention is directed to pharmaceutical compositions comprising pharmacologically effective quantities of each of a) at least one K ATP channel modulator as a first active agent and b) at least one CB x modulator as a second active agent. The invention further relates to the use of such compositions and to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans by administering such compositions to subjects in need thereof. The invention also is directed to processes of manufacturing such compositions.

    9.
    发明专利
    未知

    公开(公告)号：BRPI0517434A

    公开(公告)日：2008-10-07

    申请号：BRPI0517434

    申请日：2005-10-25

    Applicant: SOLVAY PHARM GMBH

    Inventor： FIRNGES MICHAEL ,  GREGORY PETER-COLIN ,  ANTEL JOCHEN ,  LANGE JOSEPHUS HUBERTUS MARIA ,  WALDECK HARALD

    IPC: A61K31/00 ,  A61K31/40 ,  A61K31/415 ,  A61K31/427 ,  A61K31/44 ,  A61K31/54 ,  A61P3/04 ,  C12Q1/68 ,  G01N33/00

    Abstract: Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one KATP channel opener as a first active agent and at least one CB1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATP channel opening and CB1 antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising KATP channel openers and CB1 antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined KATP channel opening and CB1 antagonistic properties.

Patent Agency Ranking